How will my country's medical device industry develop in the next 10 years?
2022-02-17
The development prospects of medical device companies seem optimistic, but the unsustainable medical costs and the participation of new competitive forces indicate that the future pattern of the industry may change. Today's manufacturers face a dilemma and risk being commoditized if they fail to establish themselves in an evolving value chain. Staying ahead is about delivering value beyond equipment and solving medical problems, not just contributing.
The Medical Device Industry in 2030 - Be Part of the Solution
Reshape business and operating models, reposition, and restructure value chains
Gone are the days of "just making equipment and selling it to healthcare providers through distributors". Value is the new synonym for success, prevention is the best diagnosis and treatment result, and intelligence is the new competitive advantage. This article explores how medical device companies can succeed through a “three-pronged” strategy in 2030.
Reshape business and operating models
Medical device companies should take a serious look at their existing organizations and reshape their traditional business and operating models for future growth by:
Incorporate intelligence into product portfolios and services to positively impact the treatment process and connect with clients, patients and consumers.
Delivering services beyond devices, intelligence beyond services - a real shift from cost to intelligence value.
Investing in enabling technologies - making the right decisions to support multiple concurrent business models individually tailored to customers, patients and consumers (potential patients) - and ultimately serve the organization's financial goals.
re-locate
Prepare for the future by thinking “from the outside in”. By 2030, the external environment will be full of variables, and medical device companies need to reposition in the new competitive landscape to deal with disruptive forces from:
New entrants, including competitors from unrelated industries.
New technology, because technological innovation will continue to outpace clinical innovation.
New markets, as developing countries continue to maintain high growth trends.
Restructure the value chain
The value chain of traditional medical devices will evolve rapidly, and by 2030, companies will play a very different role. After reshaping their business and operating models and repositioning, medical device companies need to rebuild the value chain and establish their place in the value chain. Multiple ways of "building" a value chain require companies to make fundamental strategic choices. It is now evident that manufacturers will continue to connect directly with patients and consumers, or through vertical integration with providers and even payers. The choice to rebuild the value chain is not intuitive and will likely vary according to a company's market segment (eg, device segment, business unit, and geographic region). The situation is further complicated by the dynamic evolution of the value chain itself as other companies attempt to re-architect the value chain and achieve strategic goals. However, the right choices will create enormous value for end users and help companies avoid a commoditized future.
Industry executives need to challenge conventional thinking and reimagine the role of business in 2030. Therefore, they need to re-architect their current organizations from being a value chain player to providing solutions for sustainable healthcare costs.
Beware of being caught in a dilemma
Unbearable pressure to upend the status quo
The medical device industry is expected to maintain steady growth, with annual global sales forecast to grow at a rate of more than 5% per year, reaching nearly $800 billion in sales by 2030. These forecasts reflect the continued growth in demand for innovative new devices (such as wearables) and services (such as health data) as the habitual diseases of modern life become more prevalent, as well as growth in emerging markets (especially China and India) The huge potential unleashed by economic development.
Despite the tantalizing outlook, relentless downward pressure on prices still hangs over the industry like a haze. Governments around the world are striving to reduce healthcare costs—especially in the costliest part of the healthcare system: hospitals. They want to spend less on medical devices, and at the same time want to see greater value in achieving better treatment outcomes.
Many purchasing decisions have shifted from medical institutions to economic decision makers. Despite short moratoriums like the two-year moratorium on the U.S. medical device excise tax, pricing appears to be heading in only one direction - lower. With the official implementation of EU medical device regulations in 2020 and the introduction of regulations in China to encourage local innovation, the industry will face more uncertainty in the future.
These developments have left medical device companies that have long focused on manufacturing and R&D in limbo, with medical budgets constrained and new reimbursement systems continuing to cut profits. In addition, new players (some from completely different industries) are disrupting the industry by mastering customers, patients and consumers through data. In today's volatile new market, device manufacturers, as pure commodity producers, are facing a significant risk of being caught in a dilemma along the value chain.
Evolving value chain
Competing in the future value chain of medical devices
Medical device companies have historically provided value primarily by manufacturing and selling products. However, as the pressure on the medical system increases, the medical service model has undergone fundamental changes, and therefore, the industrial value chain will usher in major changes.
In the new normal, enterprises need to break away from the role of traditional manufacturers and combine services and intelligent data with products to provide total solutions. This requires a "battle of strength" in the value chain - consolidating existing business-to-business (B2B) models and creating new ones while introducing business-to-consumer (B2C) models. The battle of power will likely include a flurry of transactional activity - mergers and acquisitions (M&A), strategic alliances and collaborations.
Ultimately, medical device companies will seek to play a more important role in the value chain, bringing closer relationships with customers, patients and consumers. Done right, it can not only add new revenue streams, but also shorten doctor visits, reduce costs, and reduce the number of doctor visits—and thus reduce healthcare costs.
Reshape business and operating models
Much more than manufacturing equipment
The industry leaders in 2030 will be those medical device companies that actively provide value by connecting with customers, patients and consumers (end users). Businesses need to move from treatment and cure to prevention, incorporating “smart” services and solutions that help reduce healthcare costs and improve outcomes. Technology will have a major impact, enabling prevention and, if still needed, a highly effective minimally invasive treatment option that reduces the time patients stay in the hospital.
In order to deliver value beyond devices in 2030, medical device companies need to carefully evaluate their business and operating models, while focusing on the following trends:
Connect with customers, patients and consumers
To reach end users, it is now more than ever for manufacturers to leverage data and add intelligence to their products—intelligence is quickly becoming an important part of the value proposition of new devices. Data and analytics tools allow businesses to connect directly and continuously with users, prioritize prevention over treatment and cure, and give patients more control over their own treatment. To rapidly improve technological capabilities and effectively introduce smart services into their product portfolios, medical device companies can consider partnering with other companies.
We've seen companies in the industry take the lead in collaborating, providing proof of this concept. Zimmer Biomet has partnered with technology platform provider HealthLoop to support patients awaiting joint replacements. HealthLoop's interactive doctor-patient app guides patients on what to do "before and after surgery," as well as collects data on surgical outcomes and post-surgery treatment to help estimate reimbursement costs. Philips took another approach to targeting end users. Philips aims to increase its market share in a wide range of areas including healthy living, prevention and diagnosis, treatment, rehabilitation and home care through its digital health platform, Philips Health Suite. The cloud-based platform leverages IoT technology to collect and analyze data from various devices and ultimately power hundreds of millions of interconnected patients, devices and sensors.
We are in one of the most challenging times in the history of healthcare, facing challenges including: population growth and aging, increasing chronic diseases, strained global resources, and the shift to value-based care. Addressing these challenges requires the use of connected healthcare IT solutions that integrate, collect, consolidate, and distribute high-quality data to generate actionable recommendations that help improve outcomes, reduce costs, and improve access to quality care.
- Jeroen Tas, Head of Innovation and Strategy, Philips
With the growing number of home medical devices (if they are wearable, they can be used anytime), the relationship with the end user has changed significantly. Clinicians use smart information to help them improve diagnosis, monitoring, and disease prevention, while patients avoid unnecessary (and costly) trips. In addition, both patients and consumers have access to valuable advice on lifestyle and diet. The number of patients undergoing remote monitoring rose 44% in 2016 and is expected to exceed 50 million by 2021, while the global market for patient remote monitoring devices is expected to reach $1.9 billion by 2025.
Manufacturers are also incorporating intelligence into devices that can provide real-time analytics based on patient data. AliveCor has developed a medical-grade electrocardiogram (ECG/EKG) strap that smartwatch wearers can use to detect stroke-causing arrhythmias, as well as measure heart rate and rhythm. The ECG strap uses a smart app to process data from the device's sensors, and also allows the wearer to make a voice recording to send to the doctor along with the ECG. Portable Medical Technology has developed an EU-certified (CE-marked) application for medical devices called ONCOassist. The software provides clinical decision support tools for oncologists with a range of prognostic aids for breast, colon, lung and gastrointestinal stromal tumors.
While these developments generate a wealth of useful data, a key challenge for medical device companies is how to monetize this information. Consumers increasingly take this information for granted and do not intend to pay for it, and as a result, revenue from consumers may be minimal. Therefore, it is necessary for medical device companies to work with payers to achieve effective commercialization and demonstrate how connectivity can actually reduce healthcare costs. In addition, the care environment will move from hospitals to the homes of patients and consumers in the future. Therefore, the customer base of medical device companies is expected to change greatly, and companies need to make fundamental adjustments to their business operation models, such as considering the impact on the future sales force.
At the same time, the proliferation of data poses another form of serious threat to the industry, cybersecurity. The connected nature of the Internet makes some medical devices vulnerable to hacking, and companies need to follow strict standards to protect patient privacy and security. In light of the spate of cyberattacks, the U.S. Food and Drug Administration (FDA) recently issued a specific guidance document dealing with vulnerabilities, Postmarket Medical Device Cybersecurity Guidance.
Despite the risks, companies should seek new ways and means to collect data for developing smart devices and connecting with end customers. As preventive and personalized care becomes the new treatment modality, technologies that support patient behavioral changes and influence patients to make positive lifestyle changes will be in great demand in the future.
Shift from cost to value
Although medical services may not be as lucrative as pure device manufacturing at the moment, companies that do not add value-added services to their product mix risk sacrificing market share and competing only in commodity markets.
More and more medical device manufacturers have introduced a range of services to complement their products. Fresenius Medical operates a chain of 3,690 dialysis centers, becoming a manufacturer of dialysis machines (50% of the total number of dialysis machines in hospitals worldwide) and an operation of dialysis clinics (as of June 2017, the company treated more than 315,000 people) patients) global leader. Fresenius has acquired US home dialysis equipment maker NxStage Medical for $2 billion, aiming to play a major role in the growing home treatment market.
Siemens renamed its medical business "Siemens Healthineers". With sales of more than $4 billion in the fourth quarter of 2017, Siemens Healthineers is the largest and most profitable business in the Siemens Group, with a profit margin of 19%. The high profit margin is mainly due to its innovative services, including managed services, consulting and technology solutions. These services and products are achieved through the establishment of strategic alliances and partnerships. Siemens recently entered into agreements with various hospitals in Turkey, mainly to manage the operation of clinical laboratory services, which are expected to benefit more than 92 million patients over the next five years.
This project, which combines our expertise in laboratory equipment with our service business, is a milestone for us and shows how we can help our customers meet the challenges they face today and enable them to excel in their fields. The new business model was designed to help our customers improve efficiency and control costs from the start.
–BerndMontag CEO SiemensHealthineers
Siemens Healthineers also has a strategic alliance with IBM Wastson Health to focus on population health management and value-based healthcare solutions for hospitals. The collaboration enables Siemens to leverage its imaging business, clinical solutions, and analyze the vast amounts of data generated by medical technology to increase understanding of disease.
While many companies have established their service business as a separate entity, we are seeing the service business gradually return to the group as it becomes part of a truly integrated core service.
Additionally, services and intelligence will drive concepts such as value-based pricing from hype to reality. In a cost-controlled healthcare system, where manufacturers deal not only with the purchasing departments of healthcare institutions, but also with economic decision makers, it is clearly necessary to strike a balance between innovation and value. For each device area in the enterprise's product portfolio, the enterprise should determine for each stakeholder, including payers, providers, patients, and to some extent even consumers, what the value means to them. In this way, companies can find opportunities to enhance product differentiation through more customer solutions, ancillary services and value-based smart devices. This, in turn, will facilitate major product portfolio decisions (including divesting low-margin businesses), as well as the development of treatment pipelines (including online, telemedicine, and remote monitoring, among others). The need to demonstrate robust clinical and economic data means that value-based pricing and innovative risk-sharing contracts will be the norm for medical device manufacturers by 2030.
To successfully collect and report measurable and valuable outcome data, medical device companies should invest in a data strategy and technology infrastructure that allows companies to clearly connect data to devices, consistently define outcomes, and increase transparency to healthcare stakeholders . To really work, the starting point should be the user experience and the corresponding difficulties, rather than the device itself, which will require a "user-based" rather than "device-oriented" perspective—a perspective that is critical to traditional businesses It may be unfamiliar, but it is already familiar to technology-based companies.
The job of reshaping business and operating models may not be easy for all companies. After all, medical devices will have to make choices by 2030 that will fundamentally change their business and operating models. Additionally, each company segment and geographic region requires a separate assessment. For example, the choices in the field of orthopedics and imaging diagnosis are different, and the choices in the United States are also different from those in China. Companies need to carefully study the treatment process for each device segment and each market in which they operate in order to decide how the business should look in the future.
Contact Info
Address: No. 1668 Huacheng Road, Jintan District, Changzhou city, Jiangsu Province
Phone: 86-519-82982668
Mobile: 86-18118332098
E-mail: 503472568@qq.com
Website
Copyright© 2022 Jiangsu Longtaifeng Medical Equipment Co., Ltd. Powered by www.300.cn
This site supports IPV6 SEO